Results 91 to 100 of about 21,874 (160)

A real-world study on treatment after TKI progression in HER2-positive MBC. [PDF]

Ther Adv Med Oncol
Li S, Zhang L, Xu T, Huang J, Zhu C, Yuan Y.   +5 more
europepmc   +1 more source

Cytotoxic Effects of Sorafenib, Lapatinib, and Bevacizumab, Alone and in Combination, on Medullary Thyroid Carcinoma Cells. [PDF]

Curr Oncol
Altun G, Yönem Ö.
europepmc   +1 more source

Targeted and systemic therapies for recurrent adult ependymomas: real-world outcomes from a single institution and concise literature review. [PDF]

Front Oncol
Maccari M, Bosio A, Caccese M, Padovan M, Guerriero A, Librizzi G, Pintacuda G, Bellu L, Fiorentino A, Volpin F, Ius T, Chioffi F, Denaro L, Lonardi S, Lombardi G.   +14 more
europepmc   +1 more source

Scaffold-free 3D-cell co-culture model system for the study of metastatic cancer in the brain TME. [PDF]

PLoS One
Sarkar P, Ahuja S, Lazar IM.
europepmc   +1 more source

Quantification of the Synergism Between HER-Targeted Drugs with Human Blood Serum and EGF. [PDF]

Acta Naturae
Kamashev DE, Leboshchina EM, Koleboshina AV, Lavrinenko IA, Vashanov GA, Nechipurenko YD.   +5 more
europepmc   +1 more source

4-Anilinoquinazoline carbamate derivatization as a platform for prodrug design and localized drug delivery. [PDF]

Bioorg Chem
Carpio MB, Walker CD, Fikes A, Laitinen T, Valdes-Pena MA, Gani O, Mallory M, Asquith CRM, Brudno Y, Pierce JG.   +9 more
europepmc   +1 more source

Efficacy and safety of pyrotinib-based regimens in patients with HER2-positive stage III/IV breast cancer: a real-world retrospective study in China. [PDF]

PeerJ
Zhi L, Huang L, Pang X, Wu Q, Lei Y.
europepmc   +1 more source

Final Efficacy and Safety Results of Pyrotinib Combined With Trastuzumab and Chemotherapy in Pre-Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. [PDF]

Cancer Med
Xie X, Huang D, Huang J, Chen X, Bai X, Zheng W, Chen L, Lan X, Song L, Lei R, Du C.   +10 more
europepmc   +1 more source

UCH-L1 down-regulates HER2 expression and increases lapatinib sensitivity by interacting with HSP90 in HER2-positive breast cancer. [PDF]

Genes Dis
Zheng M, Chen X, Gan W, Hou L, Zhou Z, Chen C, Liu Z, Cheng Y.   +7 more
europepmc   +1 more source

HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trial. [PDF]

Breast
Singer CF, Koenig F, Kacerovsky-Strobl S, Danzinger S, Brunner C, Suppan C, Deutschmann C, Balic M, Greil R, Egle D, de Azambuja E, Di Cosimo S, Choudhury A, Gnant M.   +13 more
europepmc   +1 more source